ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Sold by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. decreased its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 65.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,540 shares of the specialty pharmaceutical company’s stock after selling 2,944 shares during the period. PNC Financial Services Group Inc.’s holdings in ANI Pharmaceuticals were worth $85,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the company. Global Alpha Capital Management Ltd. grew its position in shares of ANI Pharmaceuticals by 16.4% during the fourth quarter. Global Alpha Capital Management Ltd. now owns 624,550 shares of the specialty pharmaceutical company’s stock worth $34,525,000 after acquiring an additional 88,100 shares during the last quarter. Lisanti Capital Growth LLC grew its position in ANI Pharmaceuticals by 80.4% during the 4th quarter. Lisanti Capital Growth LLC now owns 26,910 shares of the specialty pharmaceutical company’s stock worth $1,488,000 after purchasing an additional 11,990 shares during the last quarter. Raymond James Financial Inc. acquired a new position in ANI Pharmaceuticals in the fourth quarter valued at $3,916,000. Victory Capital Management Inc. raised its holdings in shares of ANI Pharmaceuticals by 6.6% in the fourth quarter. Victory Capital Management Inc. now owns 13,777 shares of the specialty pharmaceutical company’s stock valued at $762,000 after buying an additional 858 shares during the last quarter. Finally, US Bancorp DE boosted its stake in shares of ANI Pharmaceuticals by 842.9% during the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock worth $33,000 after buying an additional 531 shares during the period. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Trading Up 0.5 %

NASDAQ:ANIP opened at $66.33 on Wednesday. ANI Pharmaceuticals, Inc. has a 1 year low of $52.50 and a 1 year high of $70.31. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The stock has a fifty day moving average price of $59.88 and a two-hundred day moving average price of $58.18. The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of -120.60 and a beta of 0.63.

Analyst Upgrades and Downgrades

ANIP has been the topic of several recent research reports. Guggenheim boosted their price target on ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. JPMorgan Chase & Co. initiated coverage on ANI Pharmaceuticals in a report on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 target price on the stock. Jefferies Financial Group began coverage on ANI Pharmaceuticals in a report on Friday, March 14th. They set a “buy” rating and a $80.00 price target for the company. StockNews.com upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, March 14th. Finally, Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $79.75.

Insider Transactions at ANI Pharmaceuticals

In other news, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $60.86, for a total transaction of $60,860.00. Following the sale, the senior vice president now owns 66,525 shares of the company’s stock, valued at $4,048,711.50. The trade was a 1.48 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Meredith Cook sold 400 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total value of $25,332.00. Following the completion of the sale, the vice president now owns 80,545 shares in the company, valued at approximately $5,100,914.85. This represents a 0.49 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,200 shares of company stock valued at $191,776 in the last ninety days. 12.70% of the stock is currently owned by company insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.